Clinical outcomes in VEXAS. (A) Criteria used for presumed MDS diagnosis in VEXAS. (B) Predictors of survival using a univariate time-varying Cox model from the onset of symptoms. Variables that were significantly associated with an increased HR for mortality are highlighted by their P value (<.05). (C) Univariate logistic regression for MDS. Variables that were significantly associated with MDS are highlighted by their P value (<.05). (D) Epigenetic age and age acceleration of patients with VEXAS. Global DNA methylation was used to calculate patients’ epigenetic ages according to Horvath's clock. Patients were grouped based on their typical CH status: no typical CH, D/T (DNMT3A or TET2) mutations, D&T (DNMT3A and TET2) mutations, and mutations in other myeloid cancer genes regardless of having DNMT3A/TET2 mutations.